Information Provided By:
Fly News Breaks for November 14, 2019
RGEN
Nov 14, 2019 | 16:34 EDT
Stifel analyst Daniel Arias initiated coverage of Repligen with a Buy rating and $105 price target. As a bioproduction pure play, Repligen "sits squarely within the sweet spot" of the collective life sciences customer base, Arias tells investors in a research note. He believes the portfolio is well positioned and new products are set to launch that can drive incremental 2020 and 2021 growth.
News For RGEN From the Last 2 Days
There are no results for your query RGEN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.